Addressing Key Challenges in the Clinical Development of Combination Immuno-oncology Therapies
Immuno-oncology (I-O) has emerged as one of the most promising areas of cancer research. New immunotherapies have dramatically benefited thousands of patients, demonstrating improved median overall survival and an acceptable toxicity profile. Download this white paper to see how we have remedied four challenges in I-O combination trials:
- Planning for programs that are typically large, multinational, resource-intensive and highly specialized
- Designing innovative modernized trials
- Activating sites and enrolling patients in a competitive landscape
- Managing pseudoprogression, immune-related responses and immune-related adverse events
To download the white paper, please complete the form below. Fields marked with * are required.